NCT06705790 Exploring the Benefits of Pelvic Floor Muscle Training on Bladder, Bowel, and Sexual Function in People With Spinal Cord Injury
| NCT ID | NCT06705790 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Spinal Cord Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-06-01 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this trial is to learn about the feasibility and benefits of delivering a pelvic floor muscle training program to people with motor-incomplete spinal cord injury. The main questions it aims to answer are: 1. To evaluate the feasibility of delivering a pelvic floor muscle training program to people with spinal cord injury. The investigators will examine recruitment rate, compliance and adherence to the intervention and other study protocols, adverse events, and participant perspectives of the study protocols. 2. To explore the potential effectiveness of pelvic floor muscle training on pelvic floor, bladder, bowel, and sexual function. Participants will be asked to complete a pelvic floor muscle training program for 3 months. At the beginning, middle, and end of the program, researchers will conduct a series of tests to determine the feasibility and potential effectiveness of this program.
Eligibility Criteria
Inclusion Criteria: * Are at least 19 years of age. * Have a non-progressive, motor-incomplete spinal cord injury that is at or above the T12 neurological level at least 12 months ago. * Have symptoms of bladder, bowel, and/or sexual dysfunction that are caused by your spinal cord injury. * Have stable management of spinal cord related secondary health concerns (e.g., spasticity, neuropathic pain). * Are able to speak and understand English. Exclusion Criteria: * Are currently pregnant, have been pregnant within the past 6 months, or are planning to become pregnant in the next 6 months. * Have had urogenital surgery within the past 12 months. * Have received Botox bladder injections within the past 4 weeks, or anticipate receiving an injection in the next 6 months. * Have presence of severe medical issue that in the investigator's judgement would adversely affect the participant's participation in the study. Examples include, but are not limited to pressure sores, cardiovascular disease, and unmanaged diabetes. * Have any permanent metal fixtures in their head (excluding dental fillings), or pacemakers, stimulators, or implanted medication pumps. * Have a history of seizures, are taking medications that lower the seizure threshold, or experience recurring headaches. * Have a condition for which exercise is contraindicated.
Contact & Investigator
Tania Lam, PhD, PT
PRINCIPAL INVESTIGATOR
University of British Columbia, ICORD
Frequently Asked Questions
Who can join the NCT06705790 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06705790 currently recruiting?
Yes, NCT06705790 is actively recruiting participants. Contact the research team at alison.williams@ubc.ca for enrollment information.
Where is the NCT06705790 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT06705790 clinical trial?
NCT06705790 is sponsored by University of British Columbia. The principal investigator is Tania Lam, PhD, PT at University of British Columbia, ICORD. The trial plans to enroll 30 participants.